

Pfizer: BESPONSA™

Effective for dates of service on or after January 1, 2018, the Centers for Medicare and Medicaid Services (CMS) has granted BESPONSA™ (inotuzumab ozogamicin) injection for IV infusion the following temporary Healthcare Common Procedure Coding System (HCPCS) C-Code\*:

**C9028 – injection, inotuzumab ozogamicin, 0.1 mg**

We are respectfully requesting that you update your membership (of the individual Oncology State Societies) of this important coding change for BESPONSA. Additionally, patients receiving BESPONSA, and their providers, have access to Pfizer Oncology Together, a program that provides support to help patients get their medication, including financial assistance, treatment support, and resources to navigate potential insurance and coverage issues. Resources are available by calling 1-877-744-5675 or at [www.PfizerOncologyTogether.com](http://www.PfizerOncologyTogether.com).

Full Prescribing Information for BESPONSA:

<http://labeling.pfizer.com/ShowLabeling.aspx?id=9503>